Mohammad Athar Selected Research

lewisite

1/2021	NETosis in the pathogenesis of acute lung injury following cutaneous chemical burns.
11/2020	Cutaneous lewisite exposure causes acute lung injury.
11/2020	Protective role of HO-1 against acute kidney injury caused by cutaneous exposure to arsenicals.
1/2018	Cutaneous exposure to lewisite causes acute kidney injury by invoking DNA damage and autophagic response.
10/2016	Molecular Mechanism Underlying Pathogenesis of Lewisite-Induced Cutaneous Blistering and Inflammation: Chemical Chaperones as Potential Novel Antidotes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mohammad Athar Research Topics

Disease

98	Neoplasms (Cancer) 01/2022 - 01/2002
27	Carcinogenesis 01/2017 - 06/2002
18	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2002
18	Inflammation (Inflammations) 01/2022 - 11/2003
16	Skin Neoplasms (Skin Cancer) 01/2022 - 07/2002
12	Body Weight (Weight, Body) 08/2013 - 10/2003
11	Melanoma (Melanoma, Malignant) 01/2022 - 10/2005
11	Carcinoma (Carcinomatosis) 01/2022 - 06/2002
9	Basal Cell Carcinoma (Rodent Ulcer) 01/2018 - 03/2004
7	Residual Neoplasm 01/2022 - 08/2012
7	Glioma (Gliomas) 01/2021 - 08/2010
7	Papilloma (Papillomatosis) 01/2011 - 01/2002
6	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022 - 01/2014
5	Edema (Dropsy) 01/2022 - 11/2003
5	Chronic Obstructive Pulmonary Disease (COPD) 01/2022 - 07/2007
5	Fibrosis (Cirrhosis) 01/2021 - 01/2017
5	Hyperplasia 01/2015 - 03/2004
4	Rhabdomyosarcoma 01/2022 - 08/2010
4	Basal Cell Nevus Syndrome (Gorlin Syndrome) 01/2018 - 03/2004
3	COVID-19 01/2022 - 01/2020
3	Lung Injury 11/2020 - 11/2018
3	Pancreatic Neoplasms (Pancreatic Cancer) 09/2008 - 02/2006
2	Dysplastic Nevus Syndrome (Dysplastic Nevus) 01/2022 - 01/2021
2	Emphysema 01/2022 - 11/2018
2	Wounds and Injuries (Trauma) 01/2022 - 05/2011
2	Disease Progression 01/2022 - 01/2022
2	Ependymoma 09/2021 - 01/2019
2	Thrombophilia 08/2021 - 01/2021
2	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2021 - 01/2021
2	Retinal Degeneration 01/2021 - 01/2016
2	Hypoxia (Hypoxemia) 01/2021 - 11/2020

Drug/Important Bio-Agent (IBA)

24	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2004
15	AntioxidantsIBA 01/2015 - 06/2002
11	EnzymesIBA 10/2014 - 07/2002
10	CytokinesIBA 01/2022 - 02/2006
9	Pharmaceutical PreparationsIBA 01/2022 - 03/2004
9	Cadherins (E-Cadherin)IBA 01/2017 - 12/2008
8	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 09/2007
8	VimentinIBA 01/2021 - 07/2011
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2004
7	ArsenicIBA 10/2016 - 04/2005
6	Transcription Factors (Transcription Factor)IBA 01/2021 - 06/2009
6	Ornithine Decarboxylase (Decarboxylase, Ornithine)IBA 08/2014 - 03/2003
6	Phosphotransferases (Kinase)IBA 08/2012 - 02/2006
6	ferric nitrilotriacetateIBA 10/2010 - 07/2006
5	Cyclin D1IBA 01/2022 - 01/2002
5	LDL Receptors (LDL Receptor)IBA 01/2022 - 01/2014
5	lewisiteIBA 01/2021 - 10/2016
5	Sirolimus (Rapamycin)FDA Link 02/2019 - 05/2011
5	Fibronectins (Fibronectin)IBA 01/2016 - 07/2011
5	fisetinIBA 01/2016 - 07/2013
5	Caspase 3 (Caspase-3)IBA 01/2013 - 03/2003
5	CarcinogensIBA 01/2012 - 06/2002
5	ResveratrolIBA 05/2011 - 07/2006
5	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 07/2009 - 07/2002
5	IronIBA 09/2007 - 09/2002
4	Vitamin D FDA LinkGeneric 01/2022 - 01/2020
4	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2022 - 01/2010
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 08/2010
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 06/2009
4	CateninsIBA 05/2020 - 07/2013
4	LigandsIBA 11/2019 - 08/2010
4	anthraceneIBA 05/2016 - 01/2003
4	PolyphenolsIBA 01/2015 - 11/2002
4	Proliferating Cell Nuclear Antigen (PCNA)IBA 02/2014 - 03/2010
4	CyclinsIBA 09/2012 - 01/2002
4	Messenger RNA (mRNA)IBA 09/2008 - 10/2005
4	Free RadicalsIBA 09/2007 - 06/2002
4	TeaIBA 01/2005 - 07/2002
4	Benzoyl Peroxide FDA LinkGeneric 05/2004 - 09/2002
3	MicroRNAs (MicroRNA)IBA 01/2022 - 07/2013
3	CadmiumIBA 01/2022 - 01/2017
3	Arsenicals (Arsenic Compounds)IBA 01/2022 - 10/2016
3	Mechanistic Target of Rapamycin Complex 1IBA 01/2022 - 07/2011
3	Protons (Proton)IBA 09/2021 - 01/2019
3	Retinaldehyde (Retinal)IBA 01/2021 - 01/2021
3	oxidized low density lipoproteinIBA 11/2019 - 07/2015
3	HhAntag691IBA 12/2017 - 09/2014
3	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2016 - 01/2014
3	AcetoneIBA 08/2013 - 03/2004
3	Drinking WaterIBA 12/2011 - 01/2005
3	Glutathione (Reduced Glutathione)IBA 01/2009 - 06/2006
3	InterleukinsIBA 09/2008 - 02/2006
3	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 03/2008 - 07/2002
2	Peptides (Polypeptides)IBA 01/2022 - 03/2004
2	VaccinesIBA 01/2022 - 03/2015
2	Calcitriol (Calcijex)FDA LinkGeneric 01/2022 - 05/2020
2	Histones (Histone)IBA 01/2022 - 12/2020
2	AntigensIBA 01/2022 - 03/2004
2	Irritants (Vesicants)IBA 01/2022 - 11/2020
2	factor V LeidenIBA 08/2021 - 01/2021
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2021 - 01/2013
2	SmokeIBA 01/2021 - 11/2018
2	Oxygen (Dioxygen)IBA 01/2021 - 06/2002
2	9,10-Dimethyl-1,2-benzanthraceneIBA 01/2021 - 03/2015
2	ErbB Receptors (EGF Receptor)IBA 12/2020 - 01/2013

Therapy/Procedure

18	Therapeutics 01/2022 - 02/2006
10	Chemoprevention 01/2022 - 03/2004
4	Oral Administration 01/2011 - 02/2004
2	Immunotherapy 01/2021 - 12/2020